Global /China /Healthcare /Drug Manufacturers - General /603229

Zhejiang Ausun Pharmaceutical Co., Ltd.

603229

• SSE: 603229 • Delayed

9.83CNY 2%

1.45 USD

As of 15 June 2026, Zhejiang Ausun Pharmaceutical Co., Ltd. has a market cap of $1.18B USD, ranking #9789 globally and #2680 in China. It ranks #851 in the Healthcare sector, and #319 in the Drug Manufacturers - General industry.

Global Rank

9789

Country Rank

2680

Sector Rank

851

Industry Rank

319

Key Stats

Market Cap

$1.18BUSD

7.98B CNY

Enterprise Value

$1.07BUSD

7.21B CNY

Revenue (TTM)

$117.44MUSD

794.8M CNY

EBITDA (TTM)

$32.26MUSD

218.29M CNY

Net Income (TTM)

$15.96MUSD

108.03M CNY

EBITDA Margin

27%

Profit Margin

14%

PE Ratio

71.8

Forward PE

30.6

PS Ratio

10.0

PB Ratio

3.4

EV/EBITDA

33.1

Company Profile

Country (HQ)

China

Sector

Healthcare

Industry

Drug Manufacturers - General

CEO

Zhiguo Zheng open_in_new

Employees

1,219

Founded

2010

Website

ausunpharm.com open_in_new

warningChart data may be delayed

1d	1w	1m	3m	6m	YTD	1y	3y	5y
2%	-3.5%	-3.9%	-5.9%	-4.2%	-2.8%	24%	-17%	-19%

News

Markets

Exchange	Ticker	Price	Quotes
Shanghai Stock Exchange (SSE / SHA) MIC: XSHG PRIMARY	603229 浙江奥翔药业股份有限公司 Class A ISIN: CNE100002XK2 Shares Out.: Shares Outstanding: 825.096M¹ Shares Float: 343.891M² TV: TradingView: SSE: 603229 SA: Stock Analysis: SHA: 603229 YF: Yahoo Finance: 603229.SS GF: Google Finance: SHA: 603229 BA: Barron's: 603229 MS: Morningstar: XSHG: 603229	9.83 CNY	TV: TradingView: SSE: 603229 SA: Stock Analysis: SHA: 603229 YF: Yahoo Finance: 603229.SS GF: Google Finance: SHA: 603229 BA: Barron's: 603229 MS: Morningstar: XSHG: 603229

¹Market cap is calculated using shares outstanding.

²Float shares are publicly tradable shares, excluding insider-held stock.

About Zhejiang Ausun Pharmaceutical Co., Ltd.

Zhejiang Ausun Pharmaceutical Co., Ltd. engages in the research and development, process development, manufacture, and sale of APIs and pharmaceutical intermediates. It offers fluorine products, prostaglandins, antimicrobials, and oncology products. The company also provides products for liver disease, respiratory system, and cardiac and cerebral vessels, as well as CNS indications. In addition, it offers development and manufacturing services to the pharmaceutical, cosmetics, and nutritional industries. The company was founded in 2010 and is based in Linhai, China.

Similar Companies

Industry: Drug Manufacturers - General (China)

Name	Market Cap (USD) diff.	PE	Country
Jiangsu Hengrui Pharmaceuticals Co.,Ltd SSE: 600276	$53.92B 364.89B CNY 4K%	44.9	China
WuXi AppTec Co., Ltd. SSE: 603259	$49.7B 336.36B CNY 4K%	17.2	China
Hansoh Pharmaceutical Group Company Ltd. SHEK: 3692	$28.52B 223.48B HKD 2K%	35.7	China
Innovent Biologics, Inc. SHEK: 1801	$18.8B 147.32B HKD 1K%	162.3	China
Sichuan Biokin Pharmaceutical Co.,Ltd. SSE: 688506	$16.53B 111.89B CNY 1K%	-	China
Akeso, Inc. SHEK: 9926	$16.01B 125.46B HKD 1K%	-	China

Industry: Drug Manufacturers - General (Global)

Name	Market Cap (USD) diff.	PE	Country
Eli Lilly and Co. NYSE: LLY	$761.68B 64K%	38.1	United States
Johnson & Johnson NYSE: JNJ	$547.28B 46K%	26.4	United States
AbbVie Inc. NYSE: ABBV	$360.63B 30K%	97.4	United States
Roche Holding AG SIX: RO	$320.51B 256.25B CHF 27K%	19.9	Switzerland
AstraZeneca PLC LSE: AZN	$288.14B 215.59B GBP 24K%	27.6	United Kingdom
Merck & Co., Inc. NYSE: MRK	$274.03B 23K%	15.1	United States

chevron_leftBack